Adicet Bio, Inc.
ACETDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
3dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
ACET Earnings Report
EPS Est: $-2.42 | FQ end 2026-06
How ACET's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ADI-270 | Phase 2 | Clear Cell Renal Cell Carcinoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Adicet Bio, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Adicet Bio, Inc.'s (ACET) pipeline across Phase 2. Its lead program is ADI-270 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Adicet Bio, Inc.'s next FDA catalyst?→
Adicet Bio, Inc.'s (ACET) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ACET biotech catalysts?→
Add ACET to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Adicet Bio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.